What an Acquirer Is Actually Buying: Exit-Readiness for Healthtech, with Dr. Roxie Mooney
Most healthtech founders solve a real clinical problem, get piloted in a few systems, and then discover that solving the clinical problem was never the same thing as building a company someone would actually buy. Dr. Roxie Mooney, DBA, has spent her career on that exact gap. In this episode of The Clinical Realist, Dr. Sarah Matt talks with Dr. Roxie Mooney, founder and CEO of Legacy DNA, where she works with midmarket healthtech and pharmacy companies, often private-equity backed, who are twelve to thirty-six months out from an acquisition or a capital event. She holds a Doctorate in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.